+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Invasive Meningococcal Disease - Epidemiology Forecast to 2029

  • PDF Icon

    Clinical Trials

  • 24 Pages
  • October 2020
  • Region: Global
  • GlobalData
  • ID: 5179999
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.


Invasive meningococcal disease (IMD) is a life-threatening condition caused by the bacterium Neisseria meningitidis (N. meningitidis). N. meningitidis is an encapsulated gram-negative bacterium that exists without complication in roughly 5-11% of adults and up to 25% of adolescents. However, if the bacterium moves beyond the nasopharynx and invades body tissue, serious illness can arise, usually in the form of meningitis or septicemia. Symptoms of disease can include fever, headache, stiff neck, nausea, photophobia, and fatigue, among others. The bacterium is spread by respiratory droplets through close or prolonged contact with an infected person and is not as contagious as the common cold or flu.

In 2019, there were 3,330 laboratory-confirmed incident cases of IMD in the 9MM and this is expected to grow to 3,397 by 2029 at an annual growth rate (AGR) of 0.2%. Based on the methodologies used in this forecast, any change over the forecast period can be attributed to changes in the underlying population demographics and is not due to any direct changes in the epidemiology of IMD in any market. Serogroup B was the predominant subtype across the 9MM in 2019, but there is great variability in serogroup prevalence across all markets. In the 5EU, serogroup B was predominant in all markets, in the US serogroup Y was most predominant, in Argentina serogroup W was most prevalent, while in Brazil and China serogroup C was most prevalent.


  • This report provides an overview of the risk factors, comorbidities, and global and historical trends for invasive meningococcal disease (IMD) in the nine major markets (9MM) (US, France, Germany, Italy, Spain, UK, Argentina, Brazil, and China).
  • It includes a 10-year epidemiological forecast for laboratory-confirmed incident cases of IMD (all serogroups combined), a breakdown of laboratory-confirmed incident cases by serogroup (B, C, Y, W, and other) for 2019-2029, and the age-specific laboratory-confirmed incident cases for all serogroups combined.
  • The IMD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.

Reasons to Buy

The IMD Epidemiology series will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global IMD market.
  • Quantify patient populations in the global IMD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for IMD therapeutics in each of the markets covered.
  • Understand the predominant IMD serogroups in global markets.

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Invasive Meningococcal Disease: Executive Summary
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for Invasive Meningococcal Disease (2019-2029)
3.5.1 Laboratory-Confirmed Incident Cases of IMD
3.5.2 Laboratory-Confirmed Incident Cases of IMD by Serogroup, 2019 and 2029
3.5.3 Age-Specific Laboratory-Confirmed Incident Cases of IMD
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of Analysis
3.6.3 Strengths of Analysis
4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About the Publisher
4.4 Contact
4.5 Disclaimer
List of Tables
Table 1: Summary of Newly Added Data Types and Countries
Table 2: Summary of Updated Data Types
Table 3: Risk Factors and Comorbidities for Invasive Meningococcal Disease
List of Figures
Figure 1: 9MM, Laboratory-Confirmed Incident Cases of IMD, Men and Women, All Ages, 2019 and 2029, N
Figure 2: 9MM, Laboratory-Confirmed Incidence Rate of IMD, Cases per 100, 000 Population, Men and Women, All Ages, 2009-2019
Figure 3: 9MM, Sources Used for the Laboratory-Confirmed Incident Cases of IMD
Figure 4: 9MM, Laboratory-Confirmed Incident Cases of IMD, Men and Women, All Ages, 2019, N
Figure 5: 9MM, Laboratory-Confirmed Incident Cases of IMD by Serogroup, Men and Women, All Ages, 2019, N
Figure 6: 9MM, Laboratory-Confirmed Incident Cases of IMD by Serogroup, Men and Women, All Ages, 2029, N
Figure 7: 9MM, Laboratory-Confirmed Incident Cases of IMD by Age, Men and Women, 2019